Ngā hua rapu - Adam D. Pfefferle

  • E whakaatu ana i te 1 - 13 hua o te 13
Whakamahine hua
  1. 1
    Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression

    Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression mā Kevin Roarty, Adam D. Pfefferle, Chad J. Creighton, Charles M. Perou, Jeffrey M. Rosen

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential

    Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential mā Jelena Knežević, Adam D. Pfefferle, Ivana Petrović, Sandra B. Greene, Charles M. Perou, Jeffrey M. Rosen

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Oncogenic PI3K Mutations Lead to NF-κB–Dependent Cytokine Expression following Growth Factor Deprivation

    Oncogenic PI3K Mutations Lead to NF-κB–Dependent Cytokine Expression following Growth Factor Deprivation mā Jessica E. Hutti, Adam D. Pfefferle, Sean C. Russell, Mayukh Sircar, Charles M. Perou, Albert S. Baldwin

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Both Noncoding and Protein-Coding RNAs Contribute to Gene Expression Evolution in the Primate Brain

    Both Noncoding and Protein-Coding RNAs Contribute to Gene Expression Evolution in the Primate Brain mā Courtney C. Babbitt, Olivier Fédrigo, Adam D. Pfefferle, Alan P. Boyle, Julie E. Horvath, Terrence S. Furey, Gregory A. Wray

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis

    Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis mā J. Chuck Harrell, Adam D. Pfefferle, Nicole Zalles, Aleix Prat, Cheng Fan, Andrey Khramtsov, Olufunmilayo I. Olopade, Melissa A. Troester, Andrew C. Dudley, Charles M. Perou

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (<i>NF1</i>) as a Breast Cancer Driver

    Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (<i>NF1</i>) as a Breast Cancer Driver mā Marsha D. Wallace, Adam D. Pfefferle, Li Shen, Adrian J. McNairn, Ethan Cerami, Barbara L Fallon, Vera D. Rinaldi, Teresa Southard, Charles M. Perou, John C. Schimenti

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells

    Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells mā Patrick D. Rädler, Barbara L. Wehde, Aleata A. Triplett, Hridaya Shrestha, Jonathan H. Shepherd, Adam D. Pfefferle, Hallgeir Rui, Robert D. Cardiff, Charles M. Perou, Kay‐Uwe Wagner

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

    Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies mā Ariella B. Hanker, Adam D. Pfefferle, Justin M. Balko, María G. Kuba, Christian D. Young, Violeta Sánchez, Cammie R. Sutton, Hailing Cheng, Charles M. Perou, Jean J. Zhao, Rebecca S. Cook, Carlos L. Arteaga

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts

    Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts mā Adam D. Pfefferle, Jason I. Herschkowitz, Jerry Usary, J. Chuck Harrell, Benjamin T. Spike, Jessica R. Adams, Maria I. Torres‐Arzayus, Myles Brown, Sean E. Egan, Geoffrey M. Wahl, Jeffrey M. Rosen, Charles M. Perou

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

    Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models mā Patrick J. Roberts, Jerry Usary, David B. Darr, Patrick M. Dillon, Adam D. Pfefferle, Martin C. Whittle, James S. Duncan, Søren M. Johnson, Austin J. Combest, Jian Jin, William C. Zamboni, Gary L. Johnson, Charles M. Perou, Norman E. Sharpless

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma

    LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma mā Wenjin Liu, Kimberly B. Monahan, Adam D. Pfefferle, Takeshi Shimamura, Jessica A. Sorrentino, Keefe T. Chan, David W. Roadcap, David W. Ollila, Nancy E. Thomas, Diego H. Castrillón, C. Ryan Miller, Charles M. Perou, Kwok‐Kin Wong, James E. Bear, Norman E. Sharpless

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

    A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurren... mā Victoria Bae‐Jump, Michael W. Sill, Paola A. Gehrig, Jason D. Merker, David L. Corcoran, Adam D. Pfefferle, Michele C. Hayward, Joan L. Walker, Andrea R. Hagemann, Steven Waggoner, Roisin E. O’Cearbhaill, Megan McDonald, Mitchell I. Edelson, Paul DiSilvestro, Amy McNally, Aimee C. Fleury, Ramey D. Littell, Frederick R. Ueland, Heather A. Lankes, Carol Aghajanian

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer

    c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer mā Radhika Nair, Daniel Roden, Wee Siang Teo, Andrea McFarland, Simon Junankar, Shengzhi Ye, Akira Nguyen, Jean Yang, Iva Nikolić, Mun N. Hui, Adrienne Morey, Jaynish S. Shah, Adam D. Pfefferle, Jerry Usary, Christina Selinger, Laura A. Baker, Nicola J. Armstrong, Mark J. Cowley, Matthew J. Naylor, Christopher J. Ormandy, Sunil R. Lakhani, Jason I. Herschkowitz, Charles M. Perou, Warren Kaplan, Sandra O’Toole, Alexander Swarbrick

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: